Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECP 105

Next Previous
Search
Drug Profile

ECP 105

Alternative Names: ECP-105; Glaucoma fibrosis gene therapy - NanoGenics; LipTide-ECP105

Latest Information Update: 09 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NanoGenics
  • Class Antifibrotics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 09 Aug 2023 ECP-105 is still in preclinical studies for Fibrosis in United Kingdom (Subconjunctival) (NanoGenics pipeline, August 2023)
  • 09 Aug 2023 ECP 105 is available for licensing as of 09 Aug 2023. https://nanogenics.co.uk/en/our-pipeline (NanoGenics pipeline, August 2023)
  • 04 Dec 2018 NanoGenics plans a phase I trial for Fibrosis (glaucoma fibrosis) in fourth quarter of 2020 (NanoGenics pipeline, December 2018)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top